TrialThe lancet. Gastroenterology & hepatology2021

Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial.

Isabelle Andrieux-Meyer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.